OncoMed Pharma (OMED) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
OncoMed Pharmaceuticals Announces First Quarter 2015 Financial Results
May 7, 2015 4:06 PM EDTREDWOOD CITY, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED) today reported financial results for the quarter ended March 31, 2015 and provided an update on progress toward 2015 corporate objectives and clinical development milestones.
"The first quarter of the year has been characterized by continued pipeline progress and financial discipline. We are now conducting 16 clinical trials for six OncoMed-discovered anti-cancer stem cell therapeutics, including four randomized Phase 2 clinical trials for demcizumab and tarextumab. We recently filed an IND application with the U.S. FDA for our seventh candidate, an anti-RSPO3 antibody," said... More
